Advertisement
Screener

ROIVANT SCIENCES LTD. (ROIV) Increase (Decrease) in Other Current Assets

2.8 / 5 stars · 68/120 Roast Me

ROIVANT SCIENCES LTD. Increase (Decrease) in Other Current Assets

ROIVANT SCIENCES LTD. (ROIV) reported Increase (Decrease) in Other Current Assets of $23.84 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherCurrentAssets · last filed 2026-08-06

  • ROIVANT SCIENCES LTD. increase (decrease) in other current assets for the quarter ending 2026-06-30 was $23.84M.
  • ROIVANT SCIENCES LTD. increase (decrease) in other current assets for the quarter ending 2026-03-31 was -$18.45M.
  • ROIVANT SCIENCES LTD. increase (decrease) in other current assets for the quarter ending 2025-12-31 was $2.73M, a 93.45% decline year-over-year.
  • ROIVANT SCIENCES LTD. increase (decrease) in other current assets for the quarter ending 2025-09-30 was $4.39M.
  • ROIVANT SCIENCES LTD. increase (decrease) in other current assets for fiscal 2026 was -$11.46M, a 145.71% decline from fiscal 2025.
  • ROIVANT SCIENCES LTD. increase (decrease) in other current assets for fiscal 2025 was $25.07M, a 69.23% decline from fiscal 2024.
  • ROIVANT SCIENCES LTD. increase (decrease) in other current assets for fiscal 2024 was $81.48M, a 157.27% increase from fiscal 2023.
  • ROIVANT SCIENCES LTD. increase (decrease) in other current assets for fiscal 2023 was $31.67M, a 13.11% increase from fiscal 2022.
Period endIncrease (Decrease) in Other Current Assets 3 monthIncrease (Decrease) in Other Current Assets 6 monthIncrease (Decrease) in Other Current Assets 9 monthIncrease (Decrease) in Other Current Assets 12 month
2026-06-30$23.84M
10-Q · filed 2026-08-06
$5.38M
derived: sum of 2 quarters · filed 2026-08-06
$8.12M
derived: sum of 3 quarters · filed 2026-08-06
$12.51M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31-$18.45M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20
-$15.72M
derived: sum of 2 quarters · filed 2026-05-20
-$11.33M
derived: sum of 3 quarters · filed 2026-05-20
-$11.46M
10-K · filed 2026-05-20
2025-12-31$2.73M
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06
$7.12M
derived: sum of 2 quarters · filed 2026-02-06
$7.00M
10-Q · filed 2026-02-06
-$21.86M
derived: sum of 4 quarters · filed 2026-08-06
2025-09-30$4.39M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10
$4.26M
10-Q · filed 2025-11-10
-$24.59M
derived: sum of 3 quarters · filed 2026-08-06
$17.13M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30-$128.00K
10-Q · filed 2026-08-06
-$28.98M
derived: sum of 2 quarters · filed 2026-08-06
$12.74M
derived: sum of 3 quarters · filed 2026-08-06
$8.61M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31-$28.85M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20
$12.86M
derived: sum of 2 quarters · filed 2026-05-20
$8.74M
derived: sum of 3 quarters · filed 2026-05-20
$25.07M
10-K · filed 2026-05-20
2024-12-31$41.72M
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-06
$37.59M
derived: sum of 2 quarters · filed 2026-02-06
$53.92M
10-Q · filed 2026-02-06
$116.63M
derived: sum of 4 quarters · filed 2026-05-20
2024-09-30-$4.13M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-10
$12.21M
10-Q · filed 2025-11-10
$74.92M
derived: sum of 3 quarters · filed 2026-05-20
$67.41M
derived: sum of 4 quarters · filed 2026-05-20
2024-06-30$16.33M
10-Q · filed 2025-08-11
$79.05M
derived: sum of 2 quarters · filed 2026-05-20
$71.53M
derived: sum of 3 quarters · filed 2026-05-20
$93.17M
derived: sum of 4 quarters · filed 2026-05-20
2024-03-31$62.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20
$55.20M
derived: sum of 2 quarters · filed 2026-05-20
$76.84M
derived: sum of 3 quarters · filed 2026-05-20
$81.48M
10-K · filed 2026-05-20
2023-12-31-$7.51M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-10
$14.13M
derived: sum of 2 quarters · filed 2025-02-10
$18.77M
10-Q · filed 2025-02-10
$19.40M
derived: sum of 4 quarters · filed 2025-05-29
2023-09-30$21.64M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-12
$26.28M
10-Q · filed 2024-11-12
$26.91M
derived: sum of 3 quarters · filed 2025-05-29
$27.73M
derived: sum of 4 quarters · filed 2025-05-29
2023-06-30$4.64M
10-Q · filed 2024-08-09
$5.27M
derived: sum of 2 quarters · filed 2025-05-29
$6.09M
derived: sum of 3 quarters · filed 2025-05-29
$24.99M
derived: sum of 4 quarters · filed 2025-05-29
2023-03-31$633.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-29
$1.45M
derived: sum of 2 quarters · filed 2025-05-29
$20.36M
derived: sum of 3 quarters · filed 2025-05-29
$31.67M
10-K · filed 2025-05-29
2022-12-31$818.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-02-13
$19.72M
derived: sum of 2 quarters · filed 2024-02-13
$31.04M
10-Q · filed 2024-02-13
$42.97M
derived: sum of 4 quarters · filed 2024-02-13
2022-09-30$18.90M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-11-13
$30.22M
10-Q · filed 2023-11-13
$42.15M
derived: sum of 3 quarters · filed 2023-11-13
2022-06-30$11.31M
10-Q · filed 2023-08-14
$23.25M
derived: sum of 2 quarters · filed 2023-08-14
2022-03-31$11.94M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-06-28
$28.00M
10-K · filed 2023-06-28
2021-12-31$16.06M
10-Q · filed 2023-02-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
INSMED Inc (INSM)United States$26.566B-26.60
Zoetis Inc. (ZTS)United States$29.045B11.38
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64
Viatris Inc (VTRS)United States$20.008B-0.00
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Jazz Pharmaceuticals plc (JAZZ)$15.333B16.07
Summit Therapeutics Inc. (SMMT)United States$13.071B-13.21
BridgeBio Pharma, Inc. (BBIO)United States$12.947B-20.72
CORCEPT THERAPEUTICS INC (CORT)United States$12.804B169.10